趋势研判！2026年中国幽门螺杆菌感染药物行业产业链、市场规模、竞争企业及核心趋势分析：市场规模将有望继续攀升[图]

Core Viewpoint - The global market for Helicobacter pylori (Hp) infection treatment is experiencing growth, driven by increasing public awareness of health risks associated with Hp infection. The market is projected to reach $7.5 billion by 2025 and is expected to exceed $8 billion by 2026. In China, the market is anticipated to grow to approximately 5.7 billion yuan in 2025 and 5.9 billion yuan in 2026 [1][4][6]. Group 1: Industry Overview - Helicobacter pylori is one of the most common chronic infections globally, associated with various gastric diseases, including gastric ulcers and cancer. The treatment options include bismuth compounds, proton pump inhibitors, and antibiotics [2][3]. - The treatment landscape for Hp infection in China is diverse, with various regimens being utilized, including BQT and high-dose dual therapy. The traditional triple therapy has seen a decline in eradication rates due to antibiotic resistance [2][3]. Group 2: Market Development - The global market for Hp infection treatment is projected to grow from $5.3 billion in 2019 to $7.5 billion in 2025, with expectations to surpass $8 billion by 2026 [4][6]. - In China, the market size for Hp infection treatment is expected to reach approximately 5.7 billion yuan in 2025 and 5.9 billion yuan in 2026, following a decline due to the inclusion of antibiotics in centralized procurement projects [6]. Group 3: Industry Chain - The industry chain for Hp treatment includes upstream raw materials such as antibiotics, midstream drug development and manufacturing, and downstream sales through medical institutions and retail pharmacies [6][7]. Group 4: Competitive Landscape - Major companies in the Hp infection treatment market include Danno Pharmaceutical, Zhongsheng Pharmaceutical, Asia-Pacific Pharmaceutical, Taiji Group, and Luoxin Pharmaceutical. The market is transitioning from traditional therapies to new drug developments due to increasing antibiotic resistance [8][9]. Group 5: R&D and Treatment Trends - The current challenges in Hp treatment include high infection rates, antibiotic resistance, and low eradication rates. Traditional therapies have limitations, prompting ongoing research for innovative treatment approaches. Future trends may focus on personalized treatment, digital healthcare, and combination therapies [10][11].